Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In November 2023, J&J Surgical Vision, Inc. and Alcon, Inc. reached a settlement agreement to resolve their ongoing legal disputes related to femtosecond laser-assisted cataract surgery devices.

• In August 2023, Glaukos Corporation received FDA 510(k) clearance for its iStent Infinite product. This device is intended for standalone use to reduce elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma.

• In November 2022, Alcon, Inc. acquired Ivantis, Inc., enhancing its capabilities in the development, manufacturing, and sales of high-quality minimally invasive glaucoma surgery (MIGS) devices.

This report extensively covers different segments of Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market encompasses a diverse array of surgical techniques and devices aimed at addressing the complex challenges of glaucoma management. This market segment has been delineated by Surgery, Target, Product, and Geography to provide a comprehensive overview of the various approaches and technologies employed in MIGS procedures.

Within the realm of Surgery, MIGS encompasses a spectrum of minimally invasive techniques designed to reduce intraocular pressure (IOP) and mitigate the progression of glaucoma while minimizing trauma to ocular tissues. These surgical modalities include trabecular microbypass, supraciliary stenting, and subconjunctival drainage, among others, each offering unique advantages and outcomes for patients with different types and stages of glaucoma.

Target delineates the anatomical structures or physiological processes within the eye that MIGS devices aim to modify or bypass to achieve therapeutic effects. These targets may include the trabecular meshwork, Schlemm's canal, suprachoroidal space, or subconjunctival space, depending on the underlying pathophysiology of glaucoma and the mechanism of action of the specific MIGS device.

Product segmentation encompasses the wide range of devices and implants utilized in MIGS procedures, including trabecular microbypass stents, suprachoroidal shunts, and implantable micro-scale devices for drug delivery or drainage modulation. These products may vary in design, materials, and mechanism of action, offering ophthalmic surgeons a diverse toolkit to tailor treatment strategies to individual patient needs.

Geographic segmentation provides insights into regional trends, market dynamics, and regulatory landscapes influencing the adoption and utilization of MIGS devices across different parts of the world. Variations in healthcare infrastructure, reimbursement policies, and prevalence of glaucoma contribute to differences in market penetration and growth opportunities for MIGS manufacturers in various regions.

Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Segment Analysis

In this report, the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Surgery, Target, Product, and Geography.

Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Surgery

The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Surgery into Glaucoma in Conjunction with Cataract and Stand Alone Glaucoma.

Glaucoma in Conjunction with Cataract surgery involves the simultaneous treatment of both conditions during a single surgical procedure. This approach offers several advantages, including reduced patient burden, streamlined recovery, and potentially lower healthcare costs compared to sequential surgeries. MIGS devices utilized in conjunction with cataract surgery aim to address intraocular pressure (IOP) while preserving visual function and enhancing patient satisfaction. By integrating glaucoma management into cataract surgery, ophthalmic surgeons can effectively address both conditions, particularly in patients with coexisting cataracts and glaucoma.

On the other hand, Stand Alone Glaucoma surgery involves procedures specifically tailored to treat glaucoma without concurrent cataract extraction. These surgeries may be indicated for patients with glaucoma as the primary concern or for those who have already undergone cataract surgery but require additional IOP-lowering interventions. Stand Alone Glaucoma MIGS devices target various anatomical structures within the eye to enhance aqueous humor outflow and reduce IOP, thereby slowing the progression of glaucoma and preserving optic nerve function. This segment of the MIGS market caters to patients with a diverse range of glaucoma severities and anatomical considerations, offering innovative solutions to address their unique needs.

Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Target

The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Target into Trabecular Meshwork, Suprachoroidal Space, and Others.

The Trabecular Meshwork serves as a primary site of aqueous humor outflow resistance in the eye, making it a critical target for MIGS interventions aimed at lowering intraocular pressure (IOP). MIGS devices designed to target the trabecular meshwork facilitate aqueous humor drainage, thereby reducing IOP and alleviating the burden of glaucoma. These devices may include trabecular microbypass stents and other innovative implants that bypass or enhance the function of the trabecular meshwork to improve aqueous outflow dynamics and mitigate glaucoma progression.

The Suprachoroidal Space represents an alternative pathway for aqueous humor drainage and IOP modulation in glaucoma management. MIGS devices targeting the suprachoroidal space aim to create a direct channel for fluid egress from the anterior chamber, effectively bypassing the conventional outflow pathway. By accessing this anatomical space, MIGS procedures can reduce IOP while minimizing tissue trauma and preserving ocular anatomy. Devices designed for suprachoroidal drainage may include micro-scale implants or shunts that facilitate controlled fluid flow and maintain long-term efficacy in managing glaucoma.

Additionally, the "Others" category encompasses a variety of anatomical targets and mechanisms of action utilized in MIGS procedures. This may include devices that target the Schlemm's canal, scleral pathways, or other structures involved in aqueous humor dynamics and IOP regulation. By expanding beyond traditional targets such as the trabecular meshwork and suprachoroidal space, MIGS innovation continues to explore novel approaches to glaucoma management, offering patients and clinicians a diverse array of treatment options tailored to individual needs and anatomical considerations.

Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Product

The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Product into MIGS Stents, MIGS Shunts, and Others.

MIGS Stents represent a significant category of devices designed to facilitate aqueous humor outflow and reduce intraocular pressure (IOP) in patients with glaucoma. These micro-scale implants are typically inserted into the trabecular meshwork or Schlemm's canal to bypass or enhance conventional outflow pathways. By creating a permanent or temporary channel for fluid drainage, MIGS stents aim to restore physiological aqueous humor dynamics and mitigate the progression of glaucoma. These devices may include trabecular microbypass stents, canal-based stents, or other innovative implants designed to optimize aqueous outflow while minimizing tissue trauma and preserving ocular anatomy.

MIGS Shunts, also known as micro-shunts or aqueous drainage devices, offer an alternative approach to glaucoma management by facilitating controlled fluid egress from the anterior chamber to the subconjunctival space. These small implants are typically inserted into the anterior chamber or suprachoroidal space to create a direct pathway for aqueous humor drainage, effectively reducing IOP and alleviating the burden of glaucoma. MIGS shunts may include devices such as trabecular microbypass shunts, suprachoroidal micro-stents, or other micro-scale implants designed to modulate aqueous humor dynamics and maintain long-term efficacy in managing glaucoma.

Additionally, the "Others" category encompasses a variety of MIGS devices that may include innovative implants, instruments, or accessories used in minimally invasive glaucoma surgery. This category may encompass novel technologies targeting alternative anatomical structures or mechanisms of action to achieve IOP reduction and glaucoma management. By exploring diverse approaches to MIGS innovation, the "Others" category reflects ongoing advancements in the field of glaucoma treatment and the pursuit of tailored solutions to address the diverse needs of patients and clinicians worldwide.

Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Geography

In this report, the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Share (%), by Geographical Region, 2024

North America represents a significant market for MIGS devices, driven by advanced healthcare infrastructure, a high prevalence of glaucoma, and increasing adoption of minimally invasive surgical techniques. The region benefits from robust research and development activities, favorable reimbursement policies, and a growing emphasis on improving patient outcomes through innovative glaucoma treatment options.

Europe is another prominent market for MIGS devices, characterized by a well-established healthcare system, growing geriatric population, and increasing awareness about the benefits of minimally invasive glaucoma surgery. Market growth in Europe is supported by favorable regulatory frameworks, technological advancements, and strategic collaborations between healthcare institutions and industry players.

The Asia Pacific region is witnessing rapid growth in the MIGS devices market, driven by expanding healthcare infrastructure, rising disposable incomes, and a growing burden of glaucoma-related vision impairment. Countries such as China, India, and Japan are at the forefront of market expansion, fueled by government initiatives to improve access to quality eye care services and address the unmet needs of patients with glaucoma.

The Middle East and Africa region presents opportunities for market growth in MIGS devices, supported by increasing healthcare investments, rising awareness about eye health, and a growing prevalence of glaucoma. The region's evolving regulatory landscape, coupled with initiatives to enhance ophthalmic care infrastructure, is expected to drive market expansion in the coming years.

Latin America represents a burgeoning market for MIGS devices, fueled by improving healthcare access, rising healthcare expenditure, and a growing focus on preventive ophthalmic care. Market growth in the region is driven by initiatives to address vision impairment and blindness caused by glaucoma, along with the adoption of innovative surgical techniques to improve patient outcomes and quality of life.

This report provides an in depth analysis of various factors that impact the dynamics of Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. These factors include; Market Drivers, Restraints, and Opportunities.

Drivers:

• Rising glaucoma prevalence
• Demand surge for minimally invasive surgeries
• Aging population's susceptibility

• Increased glaucoma awareness - Increased glaucoma awareness is a significant driver for the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. With growing educational campaigns and health initiatives, both patients and healthcare providers are becoming more informed about glaucoma, its risks, and the benefits of early diagnosis and treatment. Public health organizations and medical professionals are increasingly emphasizing the importance of regular eye check-ups, especially for high-risk groups such as the elderly and those with a family history of glaucoma. This heightened awareness is leading to earlier detection and intervention, which in turn drives the demand for advanced treatment options like MIGS devices.

  Social media and online health platforms play a crucial role in spreading information about glaucoma. Influencers, health bloggers, and patient advocacy groups are actively sharing their experiences and knowledge about living with glaucoma, further increasing public awareness. The availability of more information is empowering patients to seek out innovative treatments and actively participate in their eye care management. As a result, there is a growing patient preference for minimally invasive procedures that promise effective results with fewer complications and faster recovery times compared to traditional surgeries.

  Healthcare providers are also benefiting from increased awareness as it translates to a higher number of patients seeking consultations and treatments for glaucoma. This demand encourages ophthalmologists and eye care clinics to invest in and adopt the latest MIGS technologies to provide advanced care. Manufacturers of MIGS devices are witnessing an uptick in sales and are motivated to continue developing advanced solutions to meet the growing needs of an informed and proactive patient population.

Restraints:

• Surgeon training scarcity
• Regulatory hurdles for device approval
• Efficacy and safety concerns

• Traditional treatment reluctance - Traditional treatment reluctance acts as a restraint for the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. Many patients and healthcare providers remain cautious about adopting new technologies and prefer to rely on conventional glaucoma treatments such as eye drops, laser therapy, and traditional surgical procedures. This hesitation is often due to a lack of familiarity with MIGS devices, concerns about their long-term efficacy, and potential risks associated with new surgical techniques.

  There is often skepticism about the cost-effectiveness of MIGS procedures. Traditional treatments are generally well-understood and widely covered by insurance policies, whereas newer procedures might not be as comprehensively reimbursed. This financial uncertainty can deter both patients and practitioners from opting for minimally invasive solutions despite their potential benefits.

  Additionally, some healthcare providers may lack the necessary training and expertise to perform MIGS procedures, leading to a preference for established methods they are more comfortable with. This resistance to change is compounded by the need for significant investment in new equipment and training, which can be a substantial barrier for smaller practices and clinics.

Opportunities:

• Integrated treatment protocols
• Value-based care adoption
• Patient education initiatives

• Post-market surveillance enhancement - Post-market surveillance enhancement as an opportunity in the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market can significantly contribute to the market's growth and acceptance. Improved post-market surveillance involves the systematic collection, analysis, and interpretation of data related to the performance and safety of MIGS devices after they have been approved and are in use. This can enhance the understanding of long-term outcomes, device effectiveness, and potential complications, thus building confidence among healthcare providers and patients.

  Enhanced post-market surveillance can provide valuable insights that help refine surgical techniques, improve device designs, and identify best practices for patient selection and postoperative care. This ongoing monitoring can lead to the development of more robust clinical guidelines and training programs, thereby increasing the adoption rate of MIGS procedures.

  Better surveillance can facilitate quicker identification and response to any adverse events or device malfunctions, ensuring patient safety and maintaining trust in these innovative treatments. It can also support regulatory compliance and help manufacturers demonstrate the continued efficacy and safety of their products, potentially leading to expanded indications and greater market penetration.

Key players in Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market include,

• Alcon, Inc.
• Glaukos Corporation.
• Johnson & Johnson Vision
• AbbVie Inc. (Allergan Plc.)
• Corza Ophthalmology
• Carl Zeiss Meditec AG
• Katalyst Surgical
• Lumenis Ltd
• Ziemer Ophthalmic Systems AG
• Iridex Corporation

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis